What was the primary driver of revenue growth in the first quarter of 2000?

The primary driver of revenue growth was a combination of increased sales volume for existing 'in-line' products and substantial revenue generated from product alliances. Alliance revenue, in particular, saw a significant increase of 65%.

How did the planned merger with Warner-Lambert progress during this quarter?

Pfizer's shareholders approved the issuance of Pfizer common stock in connection with the merger with Warner-Lambert Company. Warner-Lambert shareholders also approved the merger agreement. The company anticipated completing regulatory reviews and closing the merger in early June 2000, to be accounted for as a pooling-of-interests.

What is the company's outlook regarding R&D expenses?

Pfizer indicated a significant planned investment in research and development. On a standalone basis, total R&D spending was budgeted at approximately $3.2 billion for the full year 2000, and this was projected to increase to $4.7 billion when combined with Warner-Lambert's R&D efforts.

Are there any significant legal proceedings that investors should be aware of?

Pfizer is involved in various litigations, including product liability claims and governmental inquiries. Notably, there are ongoing patent infringement suits related to its nifedipine products (Procardia XL) and doxazosin (Cardura), as well as litigation concerning the Celebrex patent. The company also faces a significant trademark infringement lawsuit related to the Trovan mark, resulting in a jury award of $143 million. While the company believes most of these matters will not have a material adverse effect on its financial position or results of operations, ongoing developments should be monitored.

PFE 10-Q Quarterly Report Q2 FY2000 — Revenue, Net Income, EPS

Summary

Pfizer Inc. reported strong first-quarter 2000 results, with total revenues increasing 10% to $4.315 billion compared to the prior year period. This growth was primarily driven by a significant 65% increase in alliance revenue and an 11% rise in pharmaceutical sales, bolstered by the continued strong performance of key products like Viagra, Norvasc, and Zyrtec. Net income saw a substantial 45% increase, reaching $1.180 billion, with diluted earnings per share rising to $0.31 from $0.21 in the prior year quarter. The company also announced positive progress towards the planned merger with Warner-Lambert Company, with shareholder approvals obtained and an anticipated closing in early June 2000. The acquisition is expected to be accounted for as a pooling-of-interests. Operationally, Pfizer demonstrated improved cash flow from operations, which increased significantly to $1.064 billion from a usage of $124 million in the prior year quarter, attributed to revenue growth, improved receivables management, and lower income tax payments. While investing activities used less cash due to reduced short-term investment purchases, financing activities showed a net cash outflow of $1.540 billion, primarily due to the repayment of short-term borrowings. The company also declared a $0.09 per share second-quarter dividend.

Key Highlights

1Total revenues increased by 10% to $4.315 billion.
2Net income rose by 45% to $1.180 billion.
3Diluted earnings per share (EPS) grew by 48% to $0.31 (adjusted for stock split).
4Alliance revenue surged by 65% to $665 million, driven by product collaborations.
5Pharmaceutical revenue increased by 11% globally, with strong contributions from key products.
6Cash flow from operations turned positive, reaching $1.064 billion, a significant improvement from negative $124 million in the prior year.
7Shareholder approval for the merger with Warner-Lambert Company was obtained, with closing expected in June 2000.

PFIZER INC Quarterly Report for Q2 Ended Apr 2, 2000

Summary

Key Highlights

Frequently Asked Questions